Clinical prostate cancer最新文献_第3页

Advanced Radiation Treatment Planning of Prostate Cancer 前列腺癌的高级放射治疗计划

Clinical prostate cancer Pub Date : 2018-09-26 DOI: 10.5772/INTECHOPEN.76184

B. Tas

{"title":"Advanced Radiation Treatment Planning of Prostate Cancer","authors":"B. Tas","doi":"10.5772/INTECHOPEN.76184","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.76184","url":null,"abstract":"External beam radiotherapy has been playing a major role in the treatment of prostate cancer with excellent tumor control. Also, localization of prostate is a big challenge for excellent treatment, so we focus on actual IGRT techniques (ultrasound, EMF, etc.) for intrafraction and interfraction motion detection. We investigate several studies related with dose distribution of treatment planning techniques. Several studies have demon- strated the superiority of volumetric modulated arc therapy (VMAT) plans in prostate cancer. We also investigate hypofractionation and stereotactic radiation outcome instead of conventional fractionation for prostate cancer. We mention about prostate cancer’s treatment in future by using MR-based linac online adaptive radiotherapy. dynamic multileaf collimator (DMLC) IMRT with conventional tracking the differences between CBCT-Calypso ® and kV imaging-Calypso ® localizations are 0.31 ± 1.82, 0.00 ± 1.00, and − 028 ± 1.36 and 0.28 ± 4.12, −0.28 ± 3.22, and 0.16 ± 1.61 mm, respec -tively, in the AP, SI, and RL directions during 160 and 100 fractions each These results show good localization agreement between radiographic technique and electromagnetic transponder technique, indicating that each of the localization technique is suitable for prostate cancer. of","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"os-13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77757521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus 前列腺癌的生物标志物:基于血清前列腺特异性抗原、前列腺酸性磷酸酶、钙和磷将患者分为前列腺癌、良性前列腺增生或前列腺炎的尝试

Clinical prostate cancer Pub Date : 2017-01-12 DOI: 10.1155/2017/5687212

Shahana Sarwar, Mohammed Abdul Majid Adil, Parveen Nyamath, M. Ishaq

{"title":"Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus","authors":"Shahana Sarwar, Mohammed Abdul Majid Adil, Parveen Nyamath, M. Ishaq","doi":"10.1155/2017/5687212","DOIUrl":"https://doi.org/10.1155/2017/5687212","url":null,"abstract":"Prostatitis, BPH, and P.Ca are the most frequent pathologies of the prostate gland that are responsible for morbidity in men. Raised levels of PSA are seen in different pathological conditions involving the prostate. PAP levels are altered in inflammatory or infectious or abnormal growth of the prostate tissue. Serum calcium and phosphorus levels were also found to be altered in prostate cancer and BPH. The present study was carried out to study the levels of PSA, PAP, calcium, and phosphorus in serum of patients with Prostatitis, BPH, or P.Ca and also to evaluate the relationship between them. Males in the age group of 50–85 years with LUTS disease symptoms and with PSA levels more than 4 ng/mL were included. A total of 114 patients were analyzed including 30 controls. Prostatitis in 35.7% of cases, BPH in 35.7% of the cases, and P.Ca in 28.57% of the cases were observed. Thus, the nonmalignant cases constitute a majority. PSA, a marker specific for prostatic conditions, was significantly high in all the diseases compared to controls. A rise in serum PSA and PAP indicates prostatitis or, in combination with these two tests, decreased serum calcium shows advanced disease.","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82324763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 32

Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes 前列腺癌细胞DU145中Argonaute复合物结合mrna的分析揭示了新的miRNA靶基因

Clinical prostate cancer Pub Date : 2017-01-05 DOI: 10.1155/2017/4893921

Jaroslaw Szczyrba, V. Jung, M. Beitzinger, E. Nolte, S. Wach, Martin Hart, S. Sapich, M. Wiesehöfer, H. Taubert, G. Wennemuth, Norbert Eichner, T. Stempfl, B. Wullich, G. Meister, F. Grässer

{"title":"Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes","authors":"Jaroslaw Szczyrba, V. Jung, M. Beitzinger, E. Nolte, S. Wach, Martin Hart, S. Sapich, M. Wiesehöfer, H. Taubert, G. Wennemuth, Norbert Eichner, T. Stempfl, B. Wullich, G. Meister, F. Grässer","doi":"10.1155/2017/4893921","DOIUrl":"https://doi.org/10.1155/2017/4893921","url":null,"abstract":"Posttranscriptional gene regulation by microRNAs (miRNAs) contributes to the induction and maintenance of prostate carcinoma (PCa). To identify mRNAs enriched or removed from Ago2-containing RISC complexes, these complexes were immunoprecipitated from normal prostate fibroblasts (PNFs) and the PCa line DU145 and the bound mRNAs were quantified by microarray. The analysis of Ago complexes derived from PNFs or DU145 confirmed the enrichment or depletion of a variety of mRNAs already known from the literature to be deregulated. Novel potential targets were analyzed by luciferase assays with miRNAs known to be deregulated in PCa. We demonstrate that the mRNAs of the death effector domain-containing protein (DEDD), the tumor necrosis factor receptor superfamily, member 10b protein (TNFRSF10B), the tumor protein p53 inducible nuclear protein 1 (TP53INP1), and the secreted protein, acidic, cysteine-rich (SPARC; osteonectin) are regulated by miRNAs miR-148a, miR-20a, miR-24, and miR-29a/b, respectively. Therefore, these miRNAs represent potential targets for therapy. Surprisingly, overexpression of miR-24 induced focus formation and proliferation of DU145 cells, while miR-29b reduced proliferation. The study confirms genes deregulated in PCa by virtue of their presence/absence in the Ago2-complex. In conjunction with the already published miRNA profiles of PCa, the data can be used to identify miRNA-regulated mRNAs.","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79141318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Influence of In Utero Maternal and Neonate Factors on Cord Blood Leukocyte Telomere Length: Clues to the Racial Disparity in Prostate Cancer? 子宫内母体和新生儿因素对脐带血白细胞端粒长度的影响:前列腺癌种族差异的线索?

Clinical prostate cancer Pub Date : 2016-12-14 DOI: 10.1155/2016/3691650

Kari A. Weber, C. Heaphy, S. Rohrmann, B. Gonzalez, J. Bienstock, T. Agurs-Collins, E. Platz, A. Meeker

{"title":"Influence of In Utero Maternal and Neonate Factors on Cord Blood Leukocyte Telomere Length: Clues to the Racial Disparity in Prostate Cancer?","authors":"Kari A. Weber, C. Heaphy, S. Rohrmann, B. Gonzalez, J. Bienstock, T. Agurs-Collins, E. Platz, A. Meeker","doi":"10.1155/2016/3691650","DOIUrl":"https://doi.org/10.1155/2016/3691650","url":null,"abstract":"Background. Modifiable factors in adulthood that explain the racial disparity in prostate cancer have not been identified. Because racial differences in utero that may account for this disparity are understudied, we investigated the association of maternal and neonate factors with cord blood telomere length, as a cumulative marker of cell proliferation and oxidative damage, by race. Further, we evaluated whether cord blood telomere length differs by race. Methods. We measured venous umbilical cord blood leukocyte relative telomere length by qPCR in 38 black and 38 white full-term male neonates. Using linear regression, we estimated geometric mean relative telomere length and tested for differences by race. Results. Black mothers were younger and had higher parity and black neonates had lower birth and placental weights. These factors were not associated with relative telomere length, even after adjusting for or stratifying by race. Relative telomere length in black (2.72) and white (2.73) neonates did not differ, even after adjusting for maternal or neonate factors (all p > 0.9). Conclusions. Maternal and neonate factors were not associated with cord blood telomere length, and telomere length did not differ by race. These findings suggest that telomere length at birth does not explain the prostate cancer racial disparity.","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82460230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma 盆腔放疗与有限淋巴结取样根治性前列腺切除术治疗高级别前列腺癌的比较

Clinical prostate cancer Pub Date : 2016-03-09 DOI: 10.1155/2016/2674954

C. Baker, A. McDonald, E. Yang, R. Jacob, S. Rais-Bahrami, J. Nix, J. Fiveash

{"title":"Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma","authors":"C. Baker, A. McDonald, E. Yang, R. Jacob, S. Rais-Bahrami, J. Nix, J. Fiveash","doi":"10.1155/2016/2674954","DOIUrl":"https://doi.org/10.1155/2016/2674954","url":null,"abstract":"Purpose. To compare oncologic outcomes for patients with Gleason score (GS) ≥ 8 prostate adenocarcinoma treated with radical prostatectomy (RP) versus external beam radiotherapy combined with androgen deprivation (RT + ADT). Methods. Between 2001 and 2014, 121 patients with GS ≥ 8 were treated at our institution via RT + ADT (n = 71) or RP (n = 50) with ≥ 1 year of biochemical follow-up. Endpoints included biochemical failure (BF), distant metastasis, and initiation of salvage ADT. Results. The RT + ADT group was older, had higher biopsy GS, and had greater risk of lymph node involvement. All other pretreatment characteristics were similar between groups. Mean number of lymph nodes (LNs) sampled for patients undergoing RP was 8.2 (±6.18). Mean biochemical follow-up for all patients was 61 months. Five-year estimates of BF for the RT + ADT and RP groups were 7.2% versus 42.3%, (p < 0.001). The RT + ADT group also had lower rates of distant metastasis (2% versus 7.8%) and salvage ADT (8% versus 33.8%). Conclusion. In this analysis, RT + ADT was associated with improved biochemical and metastatic control when compared to RP with limited LN sampling. How RT + ADT compares with more aggressive lymphadenectomy, as is currently our institutional standard, remains an important unanswered question.","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89633782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Hydrogen Sulfide Signaling Axis as a Target for Prostate Cancer Therapeutics 硫化氢信号轴作为前列腺癌治疗的靶点

Clinical prostate cancer Pub Date : 2016-02-25 DOI: 10.1155/2016/8108549

Mingzhe Liu, Lingyun Wu, S. Montaut, Guangdong Yang

{"title":"Hydrogen Sulfide Signaling Axis as a Target for Prostate Cancer Therapeutics","authors":"Mingzhe Liu, Lingyun Wu, S. Montaut, Guangdong Yang","doi":"10.1155/2016/8108549","DOIUrl":"https://doi.org/10.1155/2016/8108549","url":null,"abstract":"Hydrogen sulfide (H2S) was originally considered toxic at elevated levels; however just in the past decade H2S has been proposed to be an important gasotransmitter with various physiological and pathophysiological roles in the body. H2S can be generated endogenously from L-cysteine by multiple enzymes, including cystathionine gamma-lyase, cystathionine beta-synthase, and 3-mercaptopyruvate sulfurtransferase in combination with cysteine aminotransferase. Prostate cancer is a major health concern and no effective treatment for prostate cancers is available. H2S has been shown to inhibit cell survival of androgen-independent, androgen-dependent, and antiandrogen-resistant prostate cancer cells through different mechanisms. Various H2S-releasing compounds, including sulfide salts, diallyl disulfide, diallyl trisulfide, sulforaphane, and other polysulfides, also have been shown to inhibit prostate cancer growth and metastasis. The expression of H2S-producing enzyme was reduced in both human prostate cancer tissues and prostate cancer cells. Androgen receptor (AR) signaling is indispensable for the development of castration resistant prostate cancer, and H2S was shown to inhibit AR transactivation and contributes to antiandrogen-resistant status. In this review, we summarized the current knowledge of H2S signaling in prostate cancer and described the molecular alterations, which may bring this gasotransmitter into the clinic in the near future for developing novel pharmacological and therapeutic interventions for prostate cancer.","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76998684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 28

Fortifying the Treatment of Prostate Cancer with Physical Activity 加强运动治疗前列腺癌

Clinical prostate cancer Pub Date : 2016-02-10 DOI: 10.1155/2016/9462975

C. Champ, Lanie K Francis, R. Klement, R. Dickerman, Ryan P. Smith

引用次数: 18

Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer 前列腺癌放疗后急性和晚期胃肠道毒性关系的系统综述

Clinical prostate cancer Pub Date : 2015-11-30 DOI: 10.1155/2015/624736

M. Peach, T. Showalter, N. Ohri

{"title":"Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer","authors":"M. Peach, T. Showalter, N. Ohri","doi":"10.1155/2015/624736","DOIUrl":"https://doi.org/10.1155/2015/624736","url":null,"abstract":"A small but meaningful percentage of men who are treated with external beam radiation therapy for prostate cancer will develop late gastrointestinal toxicity. While numerous strategies to prevent gastrointestinal injury have been studied, clinical trials concentrating on late toxicity have been difficult to carry out. Identification of subjects at high risk for late gastrointestinal injury could allow toxicity prevention trials to be performed using reasonable sample sizes. Acute radiation therapy toxicity has been shown to predict late toxicity in several organ systems. Late toxicities may occur as a consequential effect of acute injury. In this systematic review of published reports, we found that late gastrointestinal toxicity following prostate radiotherapy seems to be statistically and potentially causally related to acute gastrointestinal morbidity as a consequential effect. We submit that acute gastrointestinal toxicity may be used to identify at-risk patients who may benefit from additional attention for medical interventions and close follow-up to prevent late toxicity. Acute gastrointestinal toxicity could also be explored as a surrogate endpoint for late effects in prospective trials.","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"2015 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87237106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 40

Erratum to “Primary Zonal High Intensity Focused Ultrasound for Prostate Cancer: Results of a Prospective Phase IIa Feasibility Study” “原发性分区高强度聚焦超声治疗前列腺癌:前瞻性ii期可行性研究的结果”的勘误

Clinical prostate cancer Pub Date : 2014-04-30 DOI: 10.1155/2014/640859

R. V. van Velthoven, F. Aoun, K. Limani, K. Narahari, M. Lemort, A. Peltier

引用次数: 4

List of Contributors 贡献者名单

Clinical prostate cancer Pub Date : 2012-01-01 DOI: 10.1515/9783110573565-019

W. Boothby

引用次数: 0